Patents by Inventor Mohini GHATGE

Mohini GHATGE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE
    Publication number: 20240109843
    Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
    Type: Application
    Filed: November 3, 2023
    Publication date: April 4, 2024
    Inventors: Martin SAFO, Yan ZHANG, Piyusha Pradeep PAGARE, Guoyan XU, Mohini GHATGE, Jurgen VENITZ, Osheiza ABDULMALIK, Andrew FLEISCHMAN, David LIGHT, Moustafa EL-ARABY, Abdelsattar OMAR
  • AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE
    Publication number: 20220340531
    Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).
    Type: Application
    Filed: June 22, 2022
    Publication date: October 27, 2022
    Inventors: Martin K. SAFO, Yan ZHANG, Piyusha Pradeep PAGARE, Guoyan XU, Mohini GHATGE, Jurgen VENITZ, Osheiza ABDULMALIK
  • Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease
    Patent number: 11401241
    Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: August 2, 2022
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Martin K. Safo, Yan Zhang, Piyusha Pradeep Pagare, Guoyan Xu, Mohini Ghatge, Jurgen Venitz, Osheiza Abdulmalik
  • AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE
    Publication number: 20210002225
    Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).
    Type: Application
    Filed: March 18, 2019
    Publication date: January 7, 2021
    Inventors: Martin K. SAFO, Yan ZHANG, Piyusha Pradeep PARAGE, Guoyan XU, Mohini GHATGE, Jurgen VENITZ, Osheiza ABDULMALIK
  • Azolylacryloyl derivatives as therapeutic agents for sickle cell disease
    Patent number: 10344001
    Abstract: Azolylacryloyl derivatives with hypoxic properties are provided. The compounds have a generic formula: and are suitable for treating sickle cell disease and hypoxia-underlying diseases, e.g. hemorrhagic and traumatic shock, cardiac arrest and cardiogenic shock, traumatic brain injury, cancer, stroke, myocardial infarction, myocardial ischemia, vaso-occlusive crisis, etc.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 9, 2019
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, KING ABDULAZIZ UNIVERSITY, THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Martin K. Safo, Yan Zhang, Mohini Ghatge, Osheiza Abdulmalik, Abdelsattar Mansour Ebid Omar, Moustafa El-Sayed El-Araby
  • AZOLYLACRYLOYL DERIVATIVES AS THERAPEUTIC AGENTS FOR SICKLE CELL DISEASE
    Publication number: 20180282287
    Abstract: Azolylacryloyl derivatives with hypoxic properties are provided. The compounds have a generic formula: and are suitable for treating sickle cell disease and hypoxia-underlying diseases, e.g. hemorrhagic and traumatic shock, cardiac arrest and cardiogenic shock, traumatic brain injury, cancer, stroke, myocardial infarction, myocardial ischemia, vaso-occlusive crisis, etc.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 4, 2018
    Inventors: Martin K. Safo, Yan Zhang, Mohini Ghatge, Osheiza Abdulmalik, Abdelsattar Mansour Ebid Omar, Moustafa El-Sayed El-Araby
  • Allosteric hemoglobin modifiers with nitric oxide releasing moiety
    Patent number: 9765017
    Abstract: Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues are also provided.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: September 19, 2017
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Martin K. Safo, Richmond Danso-Danquah, Mohini Ghatge, Jurgen Venitz, Martin Mangino, Kevin R. Ward
  • ALLOSTERIC HEMOGLOBIN MODIFIERS WITH NITRIC OXIDE RELEASING MOIETY
    Publication number: 20160326097
    Abstract: Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues are also provided.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 10, 2016
    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Martin K. SAFO, Richmond DANSO-DANQUAH, Mohini GHATGE, Jurgen VENITZ, Martin MANGINO, Kevin R. WARD